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Abstract 
Introduction: There has been a considerable increase in the use of proton pump inhibitors (PPIs) in 
recent years due to their effectiveness versus H2 antagonists. This includes reducing GI bleeds in 
patients at risk. However, there are concerns with their long term use and potential costs. Costs can 
be reduced with increased prescribing of low cost generic PPIs. Aims: To analyse the influence of 
multiple demand-side measures in Scotland in recent years to increase the prescribing of low cost 
generic PPIs as well as encourage the prescribing of lower strength PPIs. Methods: Documenting 
utilization (mainly items dispensed) and expenditure in Scotland from 2001 to 2017 using health 
authority databases combined with documenting the multiple initiatives and measures both nationally 
and regionally. Results: The multiple measures in Scotland ensured high International non-proprietary 
name prescribing (up to 100% for some PPIs) as well as the prescribing of generic versus patented 
PPIs, with costs of generic PPIs as low as 8.5% of their pre-patent loss prices. Overall, total 
expenditure on PPIs in Scotland was 66.7% lower in 2017 at GB£18.83million compared to 2001 
levels. This was despite a 3.06-fold increase in PPI utilization during this period. The savings were 
driven by the increasing use of generic omeprazole and lansoprazole versus patent protected PPIs. 
There was also a reduction in the prescribing of high strength PPIs during this period. Conclusion: 
Multiple initiatives in Scotland in recent years have reduced expenditure on PPIs despite appreciably 
increased utilisation. Multiple initiatives have also helped to reduce the prescribing of higher strength 
PPIs. This is an exemplar to other countries seeking to enhance their prescribing efficiency.  
 
Introduction 
 
With ageing populations, the increasing prevalence of chronic diseases, and polypharmacy, the 
proton pump inhibitors (PPIs) have become one of the most prescribed medicines among Western 
countries (1-4). We are also seeing increased use of PPIs among Central and Eastern European 
(CEE) countries (2). However, this is not universal as there are prescribing restrictions and co-
payments for PPIs in some CEE countries such as Lithuania and Serbia, which appreciably limited 
their use versus Western European countries (2, 5).  
 
Upper gastrointestinal (GI) symptoms have a substantial impact on patients as well as healthcare 
utilisation across countries. For instance, up to 10% of general practitioner (GP) consultations in the 
UK are for dyspepsia (6). The prescribing of PPIs has increased in recent years with studies showing 
them to be more effective than H2 antagonists in both preventing and healing ulcers as well as 
reducing GI bleeds (7-13). This is important if patients are on long term treatment such as NSAIDs for 
pain or a combination of antiplatelet and anti-coagulant treatment (14-16). In the early 2000s, there 
were also concerns at the extent of GI bleeding causing admissions to hospitals in the UK with 
encouragement of greater use of PPIs (17, 18), although they still occur leading to over 9000 deaths 
annually in the UK (18).. As a result of these various factors, omeprazole was the most frequently 
prescribed medicine in Scotland in 2014 and 2015 (19). The high use of PPIs has also been seen in 
other countries and sectors (3, 20-25), with their usage enhanced in some countries by non-guideline 
prescribing (1). 
 
However, there are concerns that long term use of PPIs can have patient safety issues (1, 26). Safety 
concerns include increasing the rate of community acquired pneumonia, increasing the number of 
fragility fractures, as well as increasing the number of clostridium difficile infections (CDI) possibly due 
to changes in the gut microbiomes. In addition, increasing the number of norovirus infections as well 
as increasing the extent of chronic kidney disease and hypomagnesemia (19, 20, 27-37). These 
concerns have resulted in guidance from the Greater Glasgow and Clyde Health Board in Scotland 
and others to suggest that patients on PPIs long term, and at risk of osteoporosis, should have an 
adequate intake of calcium and vitamin D (19, 38). Patients on PPIs long term should also have their 
serum magnesium levels regularly checked especially if they are taking digoxin or other medicines 
known to cause hypomagnesaemia (19). PPIs should also be stopped where possible in those 
patients with suspected or actual CDIs (19, 39, 40). Such considerations though have to be balanced 
against the undoubted effectiveness of PPIs in preventing and healing ulcers, controlling symptoms of 
dyspepsia and heartburn, as well as reducing hospital admissions and deaths due to GI bleeds.  
 
Concerns with the possible adverse effects of long-term PPIs resulted in guidance to GPs in Scotland 
from mid to late 2000s onwards to prescribe the lowest possible dose, and also generally to review 
patients on PPIs long term at least annually (27, 41-43). This builds on earlier advice from NHS 
Scotland to enhance the prescribing of maintenance doses of PPIs rather than healing doses 
whenever possible as a measure of the quality of prescribing (44). The proportion of high strength 
versus low strength PPIs has subsequently been monitored and benchmarked between the different 
Regional Health Boards in Scotland as an indicator of the quality of GP prescribing, with GPs 
encouraged, as mentioned, to regularly review patients prescribed high strength PPIs (14, 16, 27, 45, 
46). Quality Indicators (process) discouraging the prescribing of high strength PPIs were also included 
in the Scottish National Therapeutic Indicators (NTI) list in 2012; however, they were dropped from 
2013 (27, 45) onwards to just concentrate on overall PPI utilisation. This change was because the 
Scottish government advisers, chaired by two of the co-authors, believed that the majority of potential 
reductions in the strength of PPIs prescribed by GPs had already taken place by 2013, and there was 
limited additional benefit to carry on with this NTI compared with other more important NTIs. If they 
wish to prescribe higher strength omeprazole, GPs were encouraged to prescribe 2 x 20mg capsules 
omeprazole rather than one 40mg capsule as this could be up to 60% less expensive.  
 
Increased prescribing of PPIs is a concern where there is limited use of low cost generic PPIs 
compared with appreciably more expensive patented PPIs as this will drive up ambulatory care 
expenditure without improving patient outcomes with all PPIs seen as essentially similar at 
comparable therapeutic doses (47). Expenditure on PPIs in countries where there have been limited 
initiatives to increase the prescribing of multiple sourced (generic) PPIs versus on patent PPIs has 
been up to ten times greater when adjusted for population size compared with  European countries 
who actively promoted the preferential prescribing of generic PPIs through multiple initiatives and 
measures (47). 
 
Such differences in expenditure are a major concern where resources are limited as this will reduce 
available resources to be spent on other priority disease area. To address this, the Scottish 
government, coupled with the Regional Health Boards in Scotland, introduced a range of measures 
and initiatives in recent years to encourage the prescribing of multiple sourced products where this 
does not compromise care (48, 49). These measures were addition to existing initiatives in Scotland 
to encourage the prescribing of lower dose PPIs as well as encourage international non-proprietary 
(INN) prescribing. Initiatives to enhance INN prescribing in Scotland included education in medical 
schools, IT support systems and prescribing targets (49-51), with the prices of generic PPIs as low as 
9% of pre-patent loss originator prices (49). Such activities are necessary in the UK to fully realise the 
savings from the availability of generics as community pharmacists are currently banned from 
substituting an originator medicine with a generic if the physician prescribes the originator (52). This is 
unlike for instance the situation in Sweden where there is compulsory generic substitution or France 
where pharmacists have agreed targets for substitution (53, 54). There is also no obligation for the 
originator company in the UK to lower its prices to be reimbursed once generics become available as 
there is no internal reference pricing system. This is unlike a number of other European countries 
(55)/RZSULFHVIRUJHQHULFVLQWKH8.IROORZHGWKHLQWURGXFWLRQRIWKHµ0¶DQGµ:¶VFKHPH
(Manufacturer and Wholesaler) in April 2005, which enhanced transparency in the prices of generics 
(50). Prior to this, prices of generics were less transparent in the UK as witnessed by generic 
manufacturers offering discounts of up to 80% or more on their list prices to increase their sales 
volumes (50). There are also no concerns with INN prescribing among GPs in the UK apart from a 
limited number of situations, unlike the situation in other European countries (52, 56-59).   
 
Initiatives to encourage the prescribing of multiple sourced (generic) PPIs first line in Scotland versus 
patented PPIs included education, prescribing targets and financial incentives (42, 48, 49). Generic 
PPIs have been endorsed over originators and patented PPIs in view of the considerable cost 
differences and limited differences in effectiveness between them at equivalent doses, with generic 
omeprazole and generic lansoprazole typically endorsed over other generic PPIs in Scotland as they 
had lower prices (19, 27, 41, 42, 49, 60, 61). These combined measures have resulted in 
considerable savings in the past in Scotland (49). This is similar to the multiple activities that have 
been instigated nationally and regionally in Scotland to enhance prescribing efficiency for lipid 
lowering medicines with similar results (62).  
 
There has also been Scottish Guidelines (SIGN - Scottish Intercollegiate Guidelines Network) issued 
in 2003 educating physicians on the management of dyspepsia including PPIs (49).  
 
In this paper, we will seek to further analyse the influence of these multiple activities instigated by the 
Scottish Government combined with the Health Boards in Scotland to improve efficient prescribing of 
PPIs in ambulatory care as well as the prescribing of lower strength PPIs. We will also evaluate the 
influence of changing PPI prices on the prescribing mix. This builds on our previous publications 
regarding policies to influence the prescribing of multiple sourced PPIs in Scotland (48, 49). We have 
concentrated on ambulatory care as there is limited prescribing of PPIs among hospital in-patients 
versus ambulatory care in Scotland (49). The findings will be used to provide guidance to countries 
struggling to provide comprehensive healthcare in the face of growing resource pressures driven by 
ageing populations with more complex diseases.  
 
Methodology 
 
To assess the utilisation and prescribing patterns of PPIs in ambulatory care in Scotland, we analysed 
the prescription costs analysis (PCA) database (63). This database is compiled by the Information 
Services Division (ISD) of NHS Scotland from 2001 to 2017 (63). This is an open source data set 
collecting data on the utilization and expenditure of medicines dispensed in community pharmacies in 
Scotland. It is a robust dataset that is regularly audited and covers the whole of Scotland rather than a 
selection of community pharmacies. NHS Scotland is a universal healthcare system serving the entire 
Scottish population (49, 62), with currently no co-payment for medicines in Scotland. 
 
Between 2001 and 2017, the Scottish NHS made 5 PPIs available to be prescribed. These included 
omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole. Information extracted from 
the PCA between 2001 and 2017 included: the generic name, commercial name(s), formulation(s), 
drug strength(s), number of dispensed units, cost per unit and total gross expenditure. All costs are 
depicted in Great Britain pounds (GB£s) and depict the gross ingredient costs (GIC) and cost per item 
for the medicines dispensed. No adjustment for inflation for the prices was made. This is in line with 
previous studies due to the rapid reduction in prices in the UK once originators such as the PPIs 
became available as generics (47-49).  
 
Whilst NHS Scotland routinely uses defined daily doses (DDDs) as well as DIDs (DDDs/ 1000 
inhabitants/ day) when discussing and presenting utilization data (16, 27), which is in line with 
international guidance (27, 45, 64), we typically used items dispensed in community pharmacies in 
this analysis, although some analyses were undertaken with DDDs. This is because we wanted to 
track actual prescriptions, especially with physicians being encouraged to prescribe lower strength 
PPIs. In the case of patients with chronic diseases such as GERD or dyspepsia, a prescription is 
usually for 28 or 56 days. However, there has been tendency in recent years for physicians to 
increase the length of a prescription to help with their growing workloads (62). However, cognizant of 
the need to regularly review the strength of PPIs prescribed for patients on long term use (19). We 
recognize this may influence the analysis of prescribing volumes when compared with DDDs, as well 
as make comparisons across countries difficult. However, our primary aim was an evaluation of 
prescribing practices in Scotland.  
 
For each PPI and year, total costs, the total number of dispensed and the expenditure they represent 
to NHS Scotland were calculated with the totals based on summation of individual items dispensed. In 
addition, DDDs were also used when researching the influence of different initiatives to encourage the 
prescribing of lower strength PPIs. The DDDs were calculated based on the number of packs 
dispensed and their strength (64). A sub-analysis of the extent of prescribing of generic versus 
originator PPIs was also undertaken again based on items dispensed. This information was plotted 
over time in years. The date at which each PPI became available as a generic in Scotland was also 
obtained from an internal NHS database. The ongoing activities within the Health Boards to improve 
the quality and efficiency of PPI prescribing have been collated using the 4E methodology, building on 
previous findings: Education, Engineering, Economics and Enforcement (48, 49, 65). Education refers 
to initiatives such as guidelines and academic detailing; engineering refers to organizational or 
managerial interventions such as prescribing indicators; economics refers to financial incentives for 
the prescriber; and enforcement refers to specific regulations from health authorities such as 
prescribing restrictions or compulsory generic substitution (48, 54, 65, 66). However, enforcement is 
very rare in Scotland unlike some other European countries including Austria, Finland, Norway and 
Sweden (66-69). 
 
No sophisticated analysis such as time-series analyses was undertaken due to the multiple measures 
and interventions instigated between 2001 and 2017, and the associated problems with conducting 
such analyses in these circumstances (70). 
 
Results 
 
Of the 5 PPIs included in this study, none were generically available in 2001. By the end of 2012, all 5 
PPIs were available as generics with different formulations and strengths (Table 1). 
 
Table 1 - PPIs and their patent expiration date in Scotland from 2001 to 2017 
 
Generic name Commercial name 
(Originator) 
Number of 
formulations and 
strengths 
Year of patent 
expiration 
Esomeprazole Nexium® 11 2009 
Lansoprazole Zoton® 10 2005 
Omeprazole Losec® 31 2002 
Pantoprazole Pantaloc Control® 5 2009 
Rabeprazole Pariet® 4 2012 
 
A variety of measures were undertaken between 2000 and 2017 to enhance the quality and efficiency 
of PPI prescribing (Table 2). 
 
  
Table 2 - Summary of principal demand-side measures introduced in Scotland between 2001 and 
2017 that influenced the utilization of PPIs (16, 19, 27, 42-45, 48, 49, 51, 61, 71, 72) 
 
Measure National or 
Regional 
Initiative 
Education 
National x Physicians typically trained in medical school to 
prescribe by INN name with follow up in the community 
coupled with IT systems. Follow up includes the use of 
decision support software as well as monitoring the 
extent of INN prescribing 
National x National guidance and guidelines (SIGN) for dyspepsia 
(withdrawn in 2015) 
National x Maintenance doses encouraged over healing doses of 
PPIs through education and benchmarking (engineering) 
as part of initiatives across Scotland to improve the 
quality of prescribing 
National and 
Regional 
x Lower strength PPIs recommended over higher strength 
PPIs in view of concerns with the long term safety of 
PPIs    
National and 
Regional 
x Regular review of patients on long term PPIs especially 
those with polypharmacy and/or at risk of osteoporosis, 
CDI and concerns with magnesium levels 
National and 
Regional 
x Esomeprazole not recommended for use in NHS 
Scotland due to price differences with other PPIs 
Regional x Regional formularies for PPIs such as the Lothian and 
Greater Glasgow and Clyde formularies advocating 
generic omeprazole. Lothian and Greater Glasgow and 
Clyde subsequently advocating both generic 
lansoprazole and omeprazole following generic 
availability of both PPIs, which has continued 
Engineering 
Regional  x Indicators to enhance the prescribing of low cost PPIs 
versus single sourced PPIs (withdrawn once the principal 
PPIs were available as generics) 
National x Benchmarking potential savings from increased generic 
prescribing 
National and 
Regional 
x Indicators (quality) and benchmarking encouraging the 
prescribing of lower strength PPIs 
Regional x Prescribing targets for esomeprazole (e.g. <4% of all PPI 
prescriptions) 
Economics Regional x Financial based prescribing incentive schemes 
Enforcement 
(Restrictions) 
National and 
Regional 
x Esomeprazole not recommended for use in NHS 
Scotland due to price differences with other PPIs 
 
Total PPI utilisation increased 3.06-fold between 2001 and 2017, rising from 1.800 million items 
dispensed in 2001 to 5.501 million items in 2017. The increase in utilisation has been driven 
predominantly by increased utilisation of omeprazole and lansoprazole with limited utilisation of the 
other PPIs (Figure 1). 
 
  
Figure 1 - Total utilisation of PPIs in Scotland between 2001 and 2017 (Items dispensed*) [Source 
ISD Scotland - (63)] 
 
 
*Items = count of the prescription items, i.e. the number of times a medicine is written onto a prescription form 
and dispensed in community pharmacies 
 
Concurrent with this, total PPI expenditure fell by 66.7% between 2001 and 2017 from GB£ 56.486 
million in 2001 to GB£18.832 million in 2017 (Figure 2). 
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Figure 2 ± Total expenditure (GB£) on PPIs in Scotland between 2001 and 2017 [Source ISD 
Scotland - (63)] 
 
 
NB. Expenditure is based on Gross Ingrenient Costs (GIC) 
 
As seen in Figure 2, PPI expenditure peaked in 2006 before falling rapidly with the availability of both 
generic omeprazole (2002) and generic lansoprazole (2005) at falling prices (Figure 3) combined with 
high rates of INN prescribing in Scotland even when only originators are available.  Table 3 contains 
details of the percentage reduction in cost/ items dispensed for the different PPIs in 2017 versus their 
prices just before patent loss (Table 1). 
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INN prescribing in terms of items dispensed varied between 96.7 and 99.1% for omeprazole in recent 
years versus 87.3% to 100% for pantoprazole, 92.6% to 99% for lansoprazole, 63.5% to 98% for 
esomeprazole and 42.6% to 96% for rabeprazole. As a result, the cost/ item dispensed for the various 
PPIs appreciably reduced following the launch of generics (Table 3). 
 
Table 3 ± Price reduction in cost/ item dispensed for the various PPIs in 2017 versus their prices just 
before patent loss [Source ISD Scotland - (63)] 
 
Proton Pump Inhibitor % reduction in 2017 
Omeprazole 91.5% 
Lansoprazole 90.1% 
Pantoprazole 89.5% 
Rabeprazole 79.6% 
Esomeprazole 73.2% 
 
There appears to be a greater reduction in the prescribing of higher strength omeprazole in recent 
years versus lansoprazole as the two most prescribed PPIs (Figures 1, 4, 5), with the dispensing of 
omeprazole further analysed in DDDs. 
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Figure 5 ± Items dispensed (20 and 40mg omeprazole) and DDDs 2001 to 2017 [Source ISD 
Scotland - (63)] 
 
 
Discussion 
 
We believe the appreciably increased prescribing of PPIs over the years (Figure 1) has been 
influenced by the high prevalence of dyspepsia in the UK, concerns with the extent of admissions to 
UK hospitals due to GI bleeding, increasing elderly patients increasing the extent of polypharmacy 
and the need for anti-coagulation as well as studies demonstrating the effectiveness of PPIs versus 
H2 antagonists in preventing as well as healing ulcers (6, 9, 10, 12, 17, 18, 73-75). However, we 
cannot say with certainty without further qualitative research.  
 
Similar to the findings with lipid lowering agents (62), the loss of a patent appears to appreciably 
influence subsequent prescribing patterns not only omeprazole following generic availability in 2002 
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(Table 1) but also for the other PPIs (Figure 1). The use of lansoprazole stabilised following the 
availability of generic omeprazole and then rose following the availability of generic lansoprazole 
(2006/ 2007 onwards ± Figure 1). This was helped by the endorsement of generic lansoprazole in 
Regional Health Board Formularies (Table 2). The utilisation of the other PPIs remained low over the 
years, enhanced by recommendations not to prescribe (Table 2, Figure 1). Such activities followed 
appreciable price differences for omeprazole and lansoprazole versus for instance esomeprazole until 
recent years (Figure 3, Table 3). These price differences are hidden from patients as there is currently 
no co-payment in Scotland; however, prices do have an indirect effect as appreciable price 
differences between different medicines in a class can result in extensive educational and other 
activities by the Scottish government and the Regional Health Boards to influence subsequent 
prescribing without compromising care (Table 2). As a result of the various initiatives, the utilisation of 
omeprazole rose 3.66 times between 2001 and 2017, greater than the overall increase in PPI 
utilisation (3.06 times). During this time, expenditure on PPIs fell by 66.7% to just GB£18.832 million 
in 2017, aided by multiple initiatives (Table 2) combined with an appreciable reduction in prices 
following generic availability (Table 3). 
 
Overall, the multiple demand-side measures (Table 2) appear to have successfully moderated or 
even reduce the prescribing of higher cost PPIs that are perceived to have no additional benefits 
(Figures 1 and 2). In addition, continuing to encourage high INN prescribing. High INN prescribing in 
Scotland is also seen in other disease areas including anti-coagulants, anti-depressants, statins for 
hypercholesterolaemia, anti-hypertensives and atypical antipsychotics for schizophrenia (48, 62, 76-
78). As a result, providing exemplars to other European countries where there are concerns with 
generics (58, 59). In addition, providing examples to other European countries with currently limited 
demand side measures resulting in the continued prescribing of higher priced patented medicines 
with limited additional benefits (47, 48, 79). This again shows how generic and patented medicines do 
interact with each other, and affect the way they are prescribed in Scotland, building on the recent 
findings with the lipid lowering therapies (62). Again, multiple demand-side measures (Table 2) 
appeared necessary to effect changes in prescribing habits, similar to other studies (25, 62, 80-82).  
 
As older PPIs lose their patent and become cheaper, moving away from patented formulations in 
favour of generic PPIs with similar efficacy and safety profiles can be a reality. This can lead to 
substantial additional savings within the NHS system despite appreciably increasing volumes (Figures 
1 and 2), although further savings can still be achieved (72). These savings can be used to fund the 
increased use of new valued but higher priced medicines as well as funding the increasing use of 
medicines in Scotland due to ageing populations within current budgets. 
 
There has been some change in the prescribing of lower strength PPIs in recent years following the 
instigation of quality indicators and other initiatives to improve the quality of PPI prescribing (Table 2, 
Figures 4 and 5). However, it is difficult to make any definite statements since GPs in Scotland have 
typically prescribed two 20mg tablets as opposed to one 40mg tablet of omeprazole as this was 
cheaper. Having said this, the prescribing of 40mg omeprazole appears to have appreciably fallen in 
recent years whilst the prescribing of 20mgs has continued to rise causing the DDDs to continue to 
rise (Figure 5). This would suggest some improvement in the quality of prescribing if patients can be 
adequately managed on 20mg of omeprazole and 15mg lansoprazole, which is the case for 
prophylaxis in patients on NSAIDs or anti-platelet medicines. This is expected to decrease 
complications from long-term use of PPIs based on available evidence (19, 27, 38, 39, 41).  
 
We are aware of a number of limitations with this study. The major ones are the fact that we cannot 
link prescribing of PPIs to any diagnoses with this dataset. In addition, there can be differences 
between prescribing and dispensing data. We also could not measure adherence rates, which can be 
a concern among patients on PPIs (83). In addition, we could not measure any improvements in long-
term outcomes from reduced prescribing of high dose PPIs with the administrative data sets we used. 
This would need access to patient level data and linked datasets. We are also aware we used GIC 
costs which includes a small discount before pharmacists are paid. Lastly, as mentioned, we 
principally used items dispensed rather than DDDs, which may lead to differences in interpretation if 
we had used DDDs. Never-the-less, we believe our findings are robust providing guidance for the 
future.   
 
  
Conclusion 
 
Multiple measures in Scotland in recent years including those affecting the prices of medicines as well 
as their usage appreciably increased the prescribing of generic (multiple sourced) PPIs versus on-
patent PPIs once they became available. This led to appreciably reduced expenditure on PPIs in 
recent years despite utilisation increasing over three-fold. There has been some reduction in the 
prescribing of higher strength PPIs in view of concerns with their long term safety; however, this 
needs further investigation before any definitive statements can be made. Overall, we believe these 
multiple activities in Scotland can be an exemplar for other countries seeking to enhance their 
prescribing efficiency.  
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